eligibility_summary
Adults ≥18 with relapsed/refractory B‑cell lymphoma (DLBCL, PMBCL, FL/tFL, MCL, MZL, CLL/SLL, Richter, Burkitt) after ≥2 lines (≥1 for MCL) incl anti‑CD20, BTKi for MCL. Must have measurable disease, 2/3 target antigens, ECOG 0–1, adequate organ/lab function. Exclude active HIV/HBV/HCV, CNS disease/seizures, serious infection, pregnancy, cardiac disease, steroids >10 mg or GVHD immunosuppression, active malignancy, hypersensitivity, ECOG ≥2, recent stroke, inability to consent/comply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ia, open-label dose-escalation of autologous tri-specific CAR T cells (CD19.20.22, cell therapy/immunotherapy) for relapsed/refractory B-cell lymphomas. Intervention: patient T cells engineered with a chimeric antigen receptor that binds CD19, CD20, and CD22 on B cells. Mechanism: CAR engagement drives CD3ζ signaling, T-cell activation, cytokine release, and cytotoxic killing, multi-antigen targeting is designed to reduce antigen escape and enhance persistence. Preconditioning: fludarabine (purine analog antimetabolite inhibiting DNA synthesis) and cyclophosphamide (alkylating agent causing DNA crosslinks) for lymphodepletion to support CAR T expansion. Target cells/pathways: malignant B cells expressing CD19/CD20/CD22, elimination via immune effector cytotoxic pathways.